IMU-381

Immunic has selected the IMU-381 program to leverage its nuclear receptor-related 1, or Nurr1, platform for neurologic, gastrointestinal and other autoimmune diseases. The platform comprises next-generation molecules, including a series of chemical derivatives, with improved overall properties. The IMU-381 program is currently in preclinical testing.